KILITCH DRUGS (INDIA) LTD. - 524500 - Board Meeting Intimation for To Consider And Approve The Un-Audited Financial Results Of The Company For The Quarter Ended June 30, 2019.
KILITCH DRUGS (INDIA) LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2019 ,inter alia, to consider and approve the un-audited financial results of the company for the quarter ended June 30, 2019. KILITCH DRUGS (INDIA) LTD. - 524500 - Shareholding for the Period Ended June 30, 2019
Kilitch Drugs India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click here KILITCH DRUGS (INDIA) LTD. - 524500 - Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0404 Name of the Signatory :- Harshal PatilDesignation :- Company Secretary and Compliance Officer Kilitch Drugs India Ltd - 524500 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are enclosing herewith certificate issued by the Registrar & Share Transfer Agent M/s. Link Intime India Private Limited confirming the compliance of Regulation 74 (5) of SEBI (Depositories and Participants) Regulations, 2018. Kilitch Drugs India Ltd - 524500 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhavin Mehta KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhavin Mehta Kilitch Drugs India Ltd - 524500 - Closure of Trading Window
With reference to the above subject, this is to inform you that pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time read with NSE Circular Reference no. NSE/CML/2019/11 and BSE Circular Reference no. LIST/COMP/01/2019-20, both dated April 02, 2019 Trading Window for dealing in Securities of the Company will remain closed for all Directors, Officers, Designated Persons of the Company and their immediate relatives with effect from Monday, July 01, 2019 till 48 hours after the declaration of Unaudited Financial Results of the Company for the quarter ended June 30, 2019. KILITCH DRUGS (INDIA) LTD. - 524500 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhavin Mehta Kilitch Drugs India Ltd - 524500 - Disclosure Of Related Party Transaction Pursuant To Regulation 23(9) Of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015
Pursuant to Regulation 23(9) of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, please find enclosed herewith disclosure of Related Party Transaction on consolidated basis for the half year ended 31st March, 2019, in the format specified on the relevant accounting standards. Kilitch Drugs India Ltd - 524500 - Disclosures under Reg. 10(5) in respect of acquisition under Reg. 10(1)(a) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Bhavin Mehta